Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and BCG in High Risk NMIBC
NCT04134000Phase 1Active, not recruiting
- Sponsor
- OncoSur
- Start
- Feb 2020
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of atezolizumab in Non-muscle-invasive bladder cancer (NMIBC), sponsored by OncoSur. Primary endpoints: Dose limiting toxicity at 24 months and Recurrence free survival at 24 months. Started Feb 2020; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04134000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04134000.